nach oben

Erschienen in:

30.01.2025 | Review Article

Topical Medications for Chronic Itch in Older Patients: Navigating a Pressing Need

verfasst von: Brooke Bartley, Christina Pierce, Chad Hivnor, Rodrigo Valdes-Rodriguez

Erschienen in: Drugs & Aging | Ausgabe 3/2025

Einloggen, um Zugang zu erhalten

Abstract

Chronic itch in older patients is a common problem, with a significant impact on quality of life. Chronic itch in the older population may be attributable to several causes, such as age-related changes, skin conditions, systemic conditions, medications, and psychological conditions. Given the complexity of itch in this population, comorbidities, and polypharmacy in most geriatric patients, treating chronic itch can be challenging for healthcare providers. Therefore, optimized topical treatment regimens are paramount to help these patients and prevent side effects.

Savin JA. How should we define itching? J Am Acad Dermatol. 1998;39:268–9. https://doi.org/10.1016/s0190-9622(98)70087-8.CrossRefPubMed

Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European s2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99:469–506. https://doi.org/10.2340/00015555-3164.CrossRefPubMed

Roh YS, Choi J, Sutaria N, Kwatra SG. Itch: epidemiology, clinical presentation, and diagnostic workup. J Am Acad Dermatol. 2022;86:1–14. https://doi.org/10.1016/j.jaad.2021.07.076.CrossRefPubMed

Matterne U, Apfelbacher CJ, Vogelgsang L, Loerbroks A, Weisshaar E. Incidence and determinants of chronic pruritus: a population-based cohort study. Acta Derm Venereol. 2013;93:532–7. https://doi.org/10.2340/00015555-1572.CrossRefPubMed

Valdes-Rodriguez R, Mollanazar NK, González-Muro J, et al. Itch prevalence and characteristics in a hispanic geriatric population: a comprehensive study using a standardized itch questionnaire. Acta Derm Venereol. 2015;95:417–21. https://doi.org/10.2340/00015555-1968.CrossRefPubMed

Ständer S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the international forum for the study of itch. Acta Derm Venereol. 2007;87:291–4. https://doi.org/10.2340/00015555-0305.CrossRefPubMed

Berger TG, Shive M, Harper GM. Pruritus in the older patient: a clinical review. JAMA. 2013;310:2443–50. https://doi.org/10.1001/jama.2013.282023.CrossRefPubMed

Berger TG, Steinhoff M. Pruritus in elderly patients—eruptions of senescence. Semin Cutan Med Surg. 2011;30:113–7. https://doi.org/10.1016/j.sder.2011.04.002.CrossRefPubMedPubMedCentral

Kaya G, Saurat JH. Dermatoporosis: a chronic cutaneous insufficiency/fragility syndrome. Clinicopathological features, mechanisms, prevention and potential treatments. Dermatology. 2007;215:284–94. https://doi.org/10.1159/000107621.CrossRefPubMed

10.

Yosipovitch G. Dry skin and impairment of barrier function associated with itch—new insights. Int J Cosmet Sci. 2004;26:1–7. https://doi.org/10.1111/j.0142-5463.2004.00199.x.CrossRefPubMed

11.

Valdes-Rodriguez R, Stull C, Yosipovitch G. Chronic pruritus in the elderly: pathophysiology, diagnosis and management. Drugs Aging. 2015;32:201–15. https://doi.org/10.1007/s40266-015-0246-0.CrossRefPubMed

12.

Steinhoff M, Al-Khawaga S, Buddenkotte J. Itch in elderly patients: origin, diagnostics, management. J Allergy Clin Immunol. 2023;152:42–9. https://doi.org/10.1016/j.jaci.2023.05.009.CrossRefPubMed

13.

van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2:Cd012119. https://doi.org/10.1002/14651858.CD012119.pub2.CrossRefPubMed

14.

Brooks SG, Mahmoud RH, Lin RR, Fluhr JW, Yosipovitch G. The skin acid mantle: an update on skin ph. J Invest Dermatol. 2024. https://doi.org/10.1016/j.jid.2024.07.009.CrossRefPubMed

15.

Kilic A, Masur C, Reich H, et al. Skin acidification with a water-in-oil emulsion (ph 4) restores disrupted epidermal barrier and improves structure of lipid lamellae in the elderly. J Dermatol. 2019;46:457–65. https://doi.org/10.1111/1346-8138.14891.CrossRefPubMedPubMedCentral

16.

Fowler JF, Nebus J, Wallo W, Eichenfield LF. Colloidal oatmeal formulations as adjunct treatments in atopic dermatitis. J Drugs Dermatol. 2012;11:804–7.PubMed

17.

Teng Y, Zhong H, Yang X, Tao X, Fan Y. Current and emerging therapies for atopic dermatitis in the elderly. Clin Interv Aging. 2023;18:1641–52. https://doi.org/10.2147/cia.S426044.CrossRefPubMedPubMedCentral

18.

Pan M, Heinecke G, Bernardo S, Tsui C, Levitt J. Urea: a comprehensive review of the clinical literature. Dermatol Online J. 2013;19:20392.CrossRefPubMed

19.

Swanbeck G, Rajka G. Antipruritic effect of urea solutions. An experimental and clinical study. Acta Derm Venereol. 1970;50:225–7.PubMed

20.

Lacarrubba F, Verzì AE, Dinotta F, Micali G. 10% urea cream in senile xerosis: clinical and instrumental evaluation. J Cosmet Dermatol. 2021;20(Suppl 1):5–8. https://doi.org/10.1111/jocd.14093.CrossRefPubMedPubMedCentral

21.

Draelos ZD. An evaluation of topical 3% salicylic acid and 1% hydrocortisone in the maintenance of scalp pruritus. J Cosmet Dermatol. 2005;4:193–7.CrossRefPubMed

22.

Yosipovitch G, Sugeng MW, Chan YH, Goon A, Ngim S, Goh CL. The effect of topically applied aspirin on localized circumscribed neurodermatitis. J Am Acad Dermatol. 2001;45:910–3. https://doi.org/10.1067/mjd.2001.117399.CrossRefPubMed

23.

Yosipovitch G, Ademola J, Lui P, Amin S, Maibach HI. Topically applied aspirin rapidly decreases histamine-induced itch. Acta Derm Venereol. 1997;77:46–8. https://doi.org/10.2340/0001555577046048.CrossRefPubMed

24.

Thomsen JS, Benfeldt E, Jensen SB, Serup J, Menné T. Topically applied aspirin decreases histamine-induced wheal and flare reactions in normal and sls-inflamed skin, but does not decrease itch. A randomized, double-blind and placebo-controlled human study. Acta Derm Venereol. 2002;82:30–5. https://doi.org/10.1080/000155502753600858.CrossRefPubMed

25.

Thomsen JS, Simonsen L, Benfeldt E, Jensen SB, Serup J. The effect of topically applied salicylic compounds on serotonin-induced scratching behaviour in hairless rats. Exp Dermatol. 2002;11:370–5. https://doi.org/10.1034/j.1600-0625.2002.110412.x.CrossRefPubMed

26.

Davies M, Marks R. Studies on the effect of salicylic acid on normal skin. Br J Dermatol. 1976;95:187–92. https://doi.org/10.1111/j.1365-2133.1976.tb00825.x.CrossRefPubMed

27.

Andoh T, Nishikawa Y, Yamaguchi-Miyamoto T, Nojima H, Narumiya S, Kuraishi Y. Thromboxane a2 induces itch-associated responses through tp receptors in the skin in mice. J Invest Dermatol. 2007;127:2042–7. https://doi.org/10.1038/sj.jid.5700810.CrossRefPubMed

28.

Lévêque JL, Corcuff P, Gonnord G, et al. Mechanism of action of a lipophilic derivative of salicylic acid on normal skin. Skin Res Technol. 1995;1:115–22. https://doi.org/10.1111/j.1600-0846.1995.tb00030.x.CrossRefPubMed

29.

Butler DC, Berger T, Elmariah S, et al. Chronic pruritus: a review. JAMA. 2024;331:2114–24. https://doi.org/10.1001/jama.2024.4899.CrossRefPubMed

30.

Yentzer BA, Ade RA, Fountain JM, et al. Improvement in treatment adherence with a 3-day course of fluocinonide cream 0.1% for atopic dermatitis. Cutis. 2010;86:208–13.PubMed

31.

Goldstein AT, Creasey A, Pfau R, Phillips D, Burrows LJ. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2011;64:e99–104. https://doi.org/10.1016/j.jaad.2010.06.011.CrossRefPubMed

32.

Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012: 561018. https://doi.org/10.1155/2012/561018.CrossRefPubMedPubMedCentral

33.

Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15. https://doi.org/10.1016/j.jaad.2005.01.010. (quiz 6–8).CrossRefPubMed

34.

Nieman LK. Consequences of systemic absorption of topical glucocorticoids. J Am Acad Dermatol. 2011;65:250–2. https://doi.org/10.1016/j.jaad.2010.12.037.CrossRefPubMedPubMedCentral

35.

Egeberg A, Thyssen JP. Topical corticosteroids in the era of new topical therapies: balancing efficacy and safety for long-term use. J Eur Acad Dermatol Venereol. 2024;38:1236–7. https://doi.org/10.1111/jdv.20041.CrossRefPubMed

36.

Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014;5:416–25. https://doi.org/10.4103/2229-5178.142483.CrossRefPubMedPubMedCentral

37.

Cubey RB. Glaucoma following the application of corticosteroid to the skin of the eyelids. Br J Dermatol. 1976;95:207–8. https://doi.org/10.1111/j.1365-2133.1976.tb00830.x.CrossRefPubMed

38.

Zugerman C, Saunders D, Levit F. Glaucoma from topically applied steroids. Arch Dermatol. 1976;112:1326. https://doi.org/10.1001/archderm.1976.01630330080032.CrossRefPubMed

39.

Nielsen NV, Sørensen PN. Glaucoma induced by application of corticosteroids to the periorbital region. Arch Dermatol. 1978;114:953–4.CrossRefPubMed

40.

Hsieh BJ, Shen D, Chan TC, Cho YT, Tang CH, Chu CY. Higher cumulative dose of topical corticosteroids is associated with osteoporosis and major osteoporotic fracture: a nationwide case–control study. J Eur Acad Dermatol Venereol. 2024;38:1347–56. https://doi.org/10.1111/jdv.19697.CrossRefPubMed

41.

Yosipovitch G, Rosen JD, Hashimoto T. Itch: From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142:1375–90. https://doi.org/10.1016/j.jaci.2018.09.005.CrossRefPubMed

42.

Luger T, Van Leent EJ, Graeber M, et al. Sdz asm 981: An emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001;144:788–94. https://doi.org/10.1046/j.1365-2133.2001.04134.x.CrossRefPubMed

43.

Van Leent EJ, De Vries HJ, Ebelin ME, Burtin P, Scott G, Bos JD. Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (elidel) for up to 1 year. J Dermatol Treat. 2007;18:19–22. https://doi.org/10.1080/09546630601121037.CrossRef

44.

Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of pimecrolimus (elidel), sd z asm 981) in patients with atopic dermatitis. Dermatology. 2002;204:63–8. https://doi.org/10.1159/000051813.CrossRefPubMed

45.

Meingassner JG, Aschauer H, Stuetz A, Billich A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol. 2005;14:752–7. https://doi.org/10.1111/j.1600-0625.2005.00354.x.CrossRefPubMed

46.

Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, sdz asm 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999;141:264–73. https://doi.org/10.1046/j.1365-2133.1999.02974.x.CrossRefPubMed

47.

Pereira U, Boulais N, Lebonvallet N, Pennec JP, Dorange G, Misery L. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol. 2010;163:70–7. https://doi.org/10.1111/j.1365-2133.2010.09757.x.CrossRefPubMed

48.

Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child. 2003;88:969–73. https://doi.org/10.1136/adc.88.11.969.CrossRefPubMedPubMedCentral

49.

Lam M, Zhu JW, Tadrous M, Drucker AM. Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta-analysis. JAMA Dermatol. 2021;157:549–58. https://doi.org/10.1001/jamadermatol.2021.0345.CrossRefPubMed

50.

Tully J, Butler DC. Topical calcineurin inhibitors in the management of chronic pruritus in older adults: a research letter. J Drugs Dermatol. 2024;23:e70–2. https://doi.org/10.36849/jdd.7190.CrossRefPubMed

51.

Chen MM, Roman SA, Sosa JA, Judson BL. The role of adjuvant therapy in the management of head and neck merkel cell carcinoma: an analysis of 4815 patients. JAMA Otolaryngol Head Neck Surg. 2014;141:137–41. https://doi.org/10.1001/jamaoto.2014.3052.CrossRef

52.

Said JT, Elman SA, Tawa M, Fisher DC, Merola JF, Kupper TS. Topical tofacitinib for the management of lymphocytic-variant hypereosinophilic syndrome with cutaneous involvement. Dermatol Ther. 2022;35: e15518. https://doi.org/10.1111/dth.15518.CrossRefPubMed

53.

Berbert Ferreira R, Berbert Ferreira S, Neves Neto AC, et al. Topical tofacitinib as effective therapy in patients with plaque psoriasis responsive to systemic drugs but with resistant nail psoriasis. Skin Appendage Disord. 2023;9:380–4. https://doi.org/10.1159/000531119.CrossRefPubMedPubMedCentral

54.

Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase iia randomized trial. Br J Dermatol. 2016;175:902–11. https://doi.org/10.1111/bjd.14871.CrossRefPubMed

55.

Berbert Ferreira S, Berbert Ferreira R, Neves Neto AC, Assef SMC, Scheinberg M. Topical tofacitinib: a janus kinase inhibitor for the treatment of vitiligo in an adolescent patient. Case Rep Dermatol. 2021;13:190–4. https://doi.org/10.1159/000513938.CrossRefPubMedPubMedCentral

56.

Sun R, Fan H, Liu J, et al. The treatment of tofacitinib for rosacea through the inhibition of the jak/stat signaling pathway. Arch Dermatol Res. 2024;316:566. https://doi.org/10.1007/s00403-024-03314-4.CrossRefPubMed

57.

Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial. BMC Dermatol. 2016;16:15. https://doi.org/10.1186/s12895-016-0051-4.CrossRefPubMedPubMedCentral

58.

Ju T, Labib A, Vander Does A, Yosipovitch G. Topical janus kinase-signal transducers and activators of transcription inhibitor tofacitinib is effective in reducing nonatopic dermatitis chronic itch: a case series. J Am Acad Dermatol. 2022;87:400–3. https://doi.org/10.1016/j.jaad.2022.03.012.CrossRefPubMed

59.

Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171:217-28.e13. https://doi.org/10.1016/j.cell.2017.08.006.CrossRefPubMedPubMedCentral

60.

Amano W, Nakajima S, Kunugi H, et al. The janus kinase inhibitor jte-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136:667-77.e7. https://doi.org/10.1016/j.jaci.2015.03.051.CrossRefPubMed

61.

Punwani N, Burn T, Scherle P, et al. Downmodulation of key inflammatory cell markers with a topical janus kinase 1/2 inhibitor. Br J Dermatol. 2015;173:989–97. https://doi.org/10.1111/bjd.13994.CrossRefPubMed

62.

Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME. Treatment of atopic dermatitis with ruxolitinib cream (jak1/jak2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145:572–82. https://doi.org/10.1016/j.jaci.2019.08.042.CrossRefPubMed

63.

Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical jak1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67:658–64. https://doi.org/10.1016/j.jaad.2011.12.018.CrossRefPubMed

64.

Duffin KC, Luchi M, Fidelus-Gort R, et al. Novel mechanism for topical treatment of plaque psoriasis-results of a randomized, double blind, concentration ranging, vehicle controlled 12 week study with jak 1/2 inhibitor incb018424 cream. J Investig Dermatol. 2010;130:S44. https://doi.org/10.1016/j.jaad.2011.12.018.CrossRef

65.

Bissonnette R, Call RS, Raoof T, et al. A maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis. Am J Clin Dermatol. 2022;23:355–64. https://doi.org/10.1007/s40257-022-00690-3.CrossRefPubMedPubMedCentral

66.

Hu W, Thornton M, Livingston RA. Real-world use of ruxolitinib cream: safety analysis at 1 year. Am J Clin Dermatol. 2024;25:327–32. https://doi.org/10.1007/s40257-023-00840-1.CrossRefPubMedPubMedCentral

67.

Kircik L, Zirwas M, Kwatra SG, et al. Rapid improvements in itch with tapinarof cream 1% once daily in two phase 3 trials in adults with mild to severe plaque psoriasis. Dermatol Ther (Heidelb). 2024;14:201–11. https://doi.org/10.1007/s13555-023-01068-x.CrossRefPubMed

68.

Silverberg J, Boguniewicz M, Rubenstein D, Tallman A, Brown P. Tapinarof cream improved itch in two phase 3 trials of moderate to severe atopic dermatitis. Ann Allergy Asthma Immunol. 2023;131:S90. https://doi.org/10.1016/j.anai.2023.08.271.CrossRef

69.

Di Meglio P, Duarte JH, Ahlfors H, et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity. 2014;40:989–1001. https://doi.org/10.1016/j.immuni.2014.04.019.CrossRefPubMedPubMedCentral

70.

Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385:2219–29. https://doi.org/10.1056/NEJMoa2103629.CrossRefPubMed

71.

Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. Roflumilast cream, 015%, for atopic dermatitis in adults and children: integument-1 and integument-2 randomized clinical trials. JAMA Dermatol. 2024;160:1161–70. https://doi.org/10.1001/jamadermatol.2024.3121.CrossRefPubMedPubMedCentral

72.

Blauvelt A, Draelos ZD, SteinGold L, et al. Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: a randomized, double-blinded, vehicle-controlled, phase 3 trial. J Am Acad Dermatol. 2024;90:986–93. https://doi.org/10.1016/j.jaad.2023.12.065.CrossRefPubMed

73.

Eichenfield LF, Gower RG, Xu J, et al. Once-daily crisaborole ointment, 2%, as a long-term maintenance treatment in patients aged ≥ 3 months with mild-to-moderate atopic dermatitis: a 52-week clinical study. Am J Clin Dermatol. 2023;24:623–35. https://doi.org/10.1007/s40257-023-00780-w.CrossRefPubMedPubMedCentral

74.

Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (pde4) inhibitor for the topical treatment of atopic dermatitis (ad) in children and adults. J Am Acad Dermatol. 2016;75:494-503.e6. https://doi.org/10.1016/j.jaad.2016.05.046.CrossRefPubMed

75.

Kitzen JM, Pergolizzi JV Jr, Taylor R Jr, Raffa RB. Crisaborole and apremilast: Pde4 inhibitors with similar mechanism of action, different indications for management of inflammatory skin conditions. Pharmacol Pharm. 2018;9:357–81. https://doi.org/10.4236/pp.2018.99028.CrossRef

76.

Lebwohl MG, Kircik LH, Moore AY, et al. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the dermis-1 and dermis-2 randomized clinical trials. JAMA. 2022;328:1073–84. https://doi.org/10.1001/jama.2022.15632.CrossRefPubMedPubMedCentral

77.

Nattkemper LA, Zhi K, Romero KE, et al. Antipruritic effect of topical acetaminophen gel in histaminergic and non-histaminergic itch provocation: a double-blind, vehicle-controlled pilot study. Acta Derm Venereol. 2022;102:adv00640. https://doi.org/10.2340/00015555-3910.CrossRefPubMed

78.

Ohashi N, Kohno T. Analgesic effect of acetaminophen: a review of known and novel mechanisms of action. Front Pharmacol. 2020;11: 580289. https://doi.org/10.3389/fphar.2020.580289.CrossRefPubMedPubMedCentral

79.

Worth H, O’Hara DV, Agarwal N, Collister D, Brennan F, Smyth B. Cannabinoids for symptom management in patients with kidney failure: a narrative review. Clin J Am Soc Nephrol. 2022;17:911–21. https://doi.org/10.2215/cjn.11560821.CrossRefPubMedPubMedCentral

80.

Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat. 2005;13:97–103.PubMed

81.

Avila C, Massick S, Kaffenberger BH, Kwatra SG, Bechtel M. Cannabinoids for the treatment of chronic pruritus: a review. J Am Acad Dermatol. 2020;82:1205–12. https://doi.org/10.1016/j.jaad.2020.01.036.CrossRefPubMed

82.

Maghfour J, Rundle CW, Rietcheck HR, et al. Assessing the effects of topical cannabidiol in patients with atopic dermatitis. Dermatol Online J. 2021, 27.

83.

Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing n-palmitoylethanolamine (atopa study). J Eur Acad Dermatol Venereol. 2008;22:73–82. https://doi.org/10.1111/j.1468-3083.2007.02351.x.CrossRefPubMed

84.

Kwiecień E, Kowalczuk D. Therapeutic potential of minor cannabinoids in dermatological diseases-a synthetic review. Molecules. 2023. https://doi.org/10.3390/molecules28166149.CrossRefPubMedPubMedCentral

85.

Phan NQ, Siepmann D, Gralow I, Ständer S. Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol Ges. 2010;8:88–91. https://doi.org/10.1111/j.1610-0387.2009.07213.x.CrossRefPubMed

86.

Ständer S, Reinhardt HW, Luger TA. [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]. Hautarzt. 2006;57:801–7. https://doi.org/10.1007/s00105-006-1180-1.CrossRefPubMed

87.

Hall N, James B, Bhuiyan MAN, Crane E, Falgout C, Murnane KS. Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain. J Cannabis Res. 2023;5:11. https://doi.org/10.1186/s42238-023-00179-8.CrossRefPubMedPubMedCentral

88.

Visse K, Blome C, Phan NQ, Augustin M, Ständer S. Efficacy of body lotion containing n-palmitoylethanolamine in subjects with chronic pruritus due to dry skin: a dermatocosmetic study. Acta Derm Venereol. 2017;97:639–41. https://doi.org/10.2340/00015555-2593.CrossRefPubMed

89.

Bromm B, Scharein E, Darsow U, Ring J. Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neurosci Lett. 1995;187:157–60. https://doi.org/10.1016/0304-3940(95)11362-z.CrossRefPubMed

90.

Yosipovitch G, Szolar C, Hui XY, Maibach H. Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin. Arch Dermatol Res. 1996;288:245–8. https://doi.org/10.1007/bf02530092.CrossRefPubMed

91.

Liu B, Jordt SE. Cooling the itch via trpm8. J Invest Dermatol. 2018;138:1254–6. https://doi.org/10.1016/j.jid.2018.01.020.CrossRefPubMedPubMedCentral

92.

Frölich M, Enk A, Diepgen TL, Weisshaar E. Successful treatment of therapy-resistant pruritus in lichen amyloidosis with menthol. Acta Derm Venereol. 2009;89:524–6. https://doi.org/10.2340/00015555-0725.CrossRefPubMed

93.

Ständer S, Augustin M, Roggenkamp D, et al. Novel trpm8 agonist cooling compound against chronic itch: results from a randomized, double-blind, controlled, pilot study in dry skin. J Eur Acad Dermatol Venereol. 2017;31:1064–8. https://doi.org/10.1111/jdv.14041.CrossRefPubMed

94.

Misery L, Santerre A, Batardière A, et al. Real-life study of anti-itching effects of a cream containing menthoxypropanediol, a trpm8 agonist, in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2019;33:e67–9. https://doi.org/10.1111/jdv.15199.CrossRefPubMed

95.

Tey HL, Tay EY, Tan WD. Safety and antipruritic efficacy of a menthol-containing moisturizing cream. Skinmed. 2017;15:437–9.PubMed

96.

Nattkemper LA, Lipman ZM, Ingrasci G, et al. Neuroimmune mediators of pruritus in hispanic scalp psoriatic itch. Acta Derm Venereol. 2023;103:adv44463. https://doi.org/10.2340/actadv.v103.4463.CrossRef

97.

Patel T, Ishiuji Y, Yosipovitch G. Menthol: A refreshing look at this ancient compound. J Am Acad Dermatol. 2007;57:873–8. https://doi.org/10.1016/j.jaad.2007.04.008.CrossRefPubMed

98.

Peier AM, Moqrich A, Hergarden AC, et al. A trp channel that senses cold stimuli and menthol. Cell. 2002;108:705–15. https://doi.org/10.1016/s0092-8674(02)00652-9.CrossRefPubMed

99.

Hoang D, Wong A, Olympia RP. Looking back to move forward: the current state of research on the clinical applications of camphor- and menthol-containing agents. Cureus. 2023;15: e41426. https://doi.org/10.7759/cureus.41426.CrossRefPubMedPubMedCentral

100.

Higashi Y, Kiuchi T, Furuta K. Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain: a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Clin Ther. 2010;32:34–43. https://doi.org/10.1016/j.clinthera.2010.01.016.CrossRefPubMed

101.

Zuccarini P, Soldani G. Camphor: benefits and risks of a widely used natural product. Acta Biol Szeged. 2009;53(2):77–82.

102.

Agrawal D, Sardana K, Mathachan SR, Bhardwaj M, Ahuja A, Jain S. A prospective study examining the effect of selected topical and systemic drugs on pruritus grading system score and stat 6 expression in patients of prurigo nodularis. Indian J Dermatol. 2021;66:638–44. https://doi.org/10.4103/ijd.ijd_341_21.CrossRefPubMedPubMedCentral

103.

Danial C, Adeduntan R, Gorell ES, et al. Evaluation of treatments for pruritus in epidermolysis bullosa. Pediatr Dermatol. 2015;32:628–34. https://doi.org/10.1111/pde.12486.CrossRefPubMed

104.

Steinhoff M, Bíró T. A tr(i)p to pruritus research: role of trpv3 in inflammation and itch. J Invest Dermatol. 2009;129:531–5. https://doi.org/10.1038/jid.2008.440.CrossRefPubMed

105.

Kotaka T, Kimura S, Kashiwayanagi M, Iwamoto J. Camphor induces cold and warm sensations with increases in skin and muscle blood flow in human. Biol Pharm Bull. 2014;37:1913–8. https://doi.org/10.1248/bpb.b14-00442.CrossRefPubMed

106.

Noiles K, Pratt M. Contact dermatitis to vicks vaporub. Dermatitis. 2010;21:167–9.CrossRefPubMed

107.

Papoiu AD, Valdes-Rodriguez R, Nattkemper LA, Chan YH, Hahn GS, Yosipovitch G. A novel topical formulation containing strontium chloride significantly reduces the intensity and duration of cowhage-induced itch. Acta Derm Venereol. 2013;93:520–6. https://doi.org/10.2340/00015555-1564.CrossRefPubMed

108.

Wood GJ, Akiyama T, Carstens E, Oaklander AL, Yosipovitch G. An insatiable itch. J Pain. 2009;10:792–7. https://doi.org/10.1016/j.jpain.2009.04.002.CrossRefPubMed

109.

Zeidler C, Lüling H, Dieckhöfer A, et al. Capsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus? Br J Dermatol. 2015;172:1669–71. https://doi.org/10.1111/bjd.13501.CrossRefPubMed

110.

Misery L, Erfan N, Castela E, et al. Successful treatment of refractory neuropathic pruritus with capsaicin 8% patch: a bicentric retrospective study with long-term follow-up. Acta Derm Venereol. 2015;95:864–5. https://doi.org/10.2340/00015555-2085.CrossRefPubMed

111.

Lysy J, Sistiery-Ittah M, Israelit Y, et al. Topical capsaicin–a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study. Gut. 2003;52:1323–6. https://doi.org/10.1136/gut.52.9.1323.CrossRefPubMedPubMedCentral

112.

Papoiu AD, Yosipovitch G. Topical capsaicin. The fire of a ‘hot’ medicine is reignited. Expert Opin Pharmacother. 2010;11:1359–71. https://doi.org/10.1517/14656566.2010.481670.CrossRefPubMed

113.

Rosen JD, Fostini AC, Yosipovitch G. Diagnosis and management of neuropathic itch. Dermatol Clin. 2018;36:213–24. https://doi.org/10.1016/j.det.2018.02.005.CrossRefPubMed

114.

Frias B, Merighi A. Capsaicin, nociception and pain. Molecules. 2016. https://doi.org/10.3390/molecules21060797.CrossRefPubMedPubMedCentral

115.

Webster LR, Nunez M, Tark MD, et al. Tolerability of ngx-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia. BMC Anesthesiol. 2011;11:25. https://doi.org/10.1186/1471-2253-11-25.CrossRefPubMedPubMedCentral

116.

Fölster-Holst R, Brasch J. Effect of topically applied capsaicin on pruritus in patients with atopic dermatitis. J Dermatol Treat. 1996;7:13–5. https://doi.org/10.3109/09546639609086862.CrossRef

117.

Yosipovitch G, Maibach HI, Rowbotham MC. Effect of emla pre-treatment on capsaicin-induced burning and hyperalgesia. Acta Derm Venereol. 1999;79:118–21. https://doi.org/10.1080/000155599750011327.CrossRefPubMed

118.

Fuchs PN, Pappagallo M, Meyer RA. Topical emla pre-treatment fails to decrease the pain induced by 1% topical capsaicin. Pain. 1999;80:637–42. https://doi.org/10.1016/s0304-3959(98)00260-7.CrossRefPubMed

119.

Choi DS, Ji Y, Jang Y, Lee WJ, Shim WS. Crotamiton, an anti-scabies agent, suppresses histamine- and chloroquine-induced itch pathways in sensory neurons and alleviates scratching in mice. Biomol Ther (Seoul). 2020;28:569–75. https://doi.org/10.4062/biomolther.2020.063.CrossRefPubMed

120.

Sekine R, Satoh T, Takaoka A, Saeki K, Yokozeki H. Anti pruritic effects of topical crotamiton, capsaicin, and a corticosteroid on pruritogen-induced scratching behavior. Exp Dermatol. 2012;21:201–4. https://doi.org/10.1111/j.1600-0625.2011.01433.x.CrossRefPubMed

121.

Thadanipon K, Anothaisintawee T, Rattanasiri S, Thakkinstian A, Attia J. Efficacy and safety of antiscabietic agents: a systematic review and network meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2019;80:1435–44. https://doi.org/10.1016/j.jaad.2019.01.004.CrossRefPubMed

122.

Smith EB, King CA, Baker MD. Crotamiton lotion in pruritus. Int J Dermatol. 1984;23:684–5. https://doi.org/10.1111/j.1365-4362.1984.tb01235.x.CrossRefPubMed

123.

Kittaka H, Yamanoi Y, Tominaga M. Transient receptor potential vanilloid 4 (trpv4) channel as a target of crotamiton and its bimodal effects. Pflugers Arch. 2017;469:1313–23. https://doi.org/10.1007/s00424-017-1998-7.CrossRefPubMed

124.

Hahn GS. Strontium is a potent and selective inhibitor of sensory irritation. Dermatol Surg. 1999;25:689–94. https://doi.org/10.1046/j.1524-4725.1999.99099.x.CrossRefPubMed

125.

Zhai H, Hannon W, Hahn GS, Harper RA, Pelosi A, Maibach HI. Strontium nitrate decreased histamine-induced itch magnitude and duration in man. Dermatology. 2000;200:244–6. https://doi.org/10.1159/000018367.CrossRefPubMed

126.

Celerier P, Richard A, Litoux P, Dreno B. Modulatory effects of selenium and strontium salts on keratinocyte-derived inflammatory cytokines. Arch Dermatol Res. 1995;287:680–2. https://doi.org/10.1007/bf00371742.CrossRefPubMed

127.

Berksoy Hayta S, Durmuş K, Altuntaş EE, Yildiz E, Hisarciklıo M, Akyol M. The reduction in inflammation and impairment in wound healing by using strontium chloride hexahydrate. Cutan Ocul Toxicol. 2018;37:24–8. https://doi.org/10.1080/15569527.2017.1326497.CrossRefPubMed

128.

Grove G, Zerweck C. An evaluation of the moisturizing and anti-itch effects of a lactic acid and pramoxine hydrochloride cream. Cutis. 2004;73:135–9.PubMed

129.

Young TA, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatol Treat. 2009;20:76–81. https://doi.org/10.1080/09546630802441218.CrossRef

130.

Kircik LH. Efficacy and onset of action of hydrocortisone acetate 2.5% and pramoxine hydrochloride 1% lotion for the management of pruritus: results of a pilot study. J Clin Aesthet Dermatol. 2011;4:48–50.PubMedPubMedCentral

131.

Zirwas MJ, Barkovic S. Anti-pruritic efficacy of itch relief lotion and cream in patients with atopic history: comparison with hydrocortisone cream. J Drugs Dermatol. 2017;16:243–7.PubMed

132.

Allenby CF, Johnstone RS, Chatfield S, Pike LC, Tidy G. Perinal—a new no-touch spray to relieve the symptoms of pruritus ani. Int J Colorectal Dis. 1993;8:184–7. https://doi.org/10.1007/bf00290302.CrossRefPubMed

133.

Lee HG, Grossman SK, Valdes-Rodriguez R, et al. Topical ketamine-amitriptyline-lidocaine for chronic pruritus: a retrospective study assessing efficacy and tolerability. J Am Acad Dermatol. 2017;76:760–1. https://doi.org/10.1016/j.jaad.2016.10.030.CrossRefPubMed

134.

He A, Kwatra SG, Sharma D, Matsuda KM. The role of topical anesthetics in the management of chronic pruritus. J Dermatol Treat. 2017;28:338–41. https://doi.org/10.1080/09546634.2016.1243787.CrossRef

135.

Kumar M, Chawla R, Goyal M. Topical anesthesia. J Anaesthesiol Clin Pharmacol. 2015;31:450–6. https://doi.org/10.4103/0970-9185.169049.CrossRefPubMedPubMedCentral

136.

Marra DE, Yip D, Fincher EF, Moy RL. Systemic toxicity from topically applied lidocaine in conjunction with fractional photothermolysis. Arch Dermatol. 2006;142:1024–6. https://doi.org/10.1001/archderm.142.8.1024.CrossRefPubMed

137.

Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin study group. Arch Dermatol. 1995;131:1403–8.CrossRefPubMed

138.

Aliotta GE, LoVecchio S, Elberling J, Arendt-Nielsen L. Antipruritic effects of doxepin cream on experimentally induced histaminergic and nonhistaminergic itch. Dermatol Ther. 2023;2023:9926108. https://doi.org/10.1155/2023/9926108.CrossRef

139.

Greiding L, Moreno P. Doxepin incorporated into a dermatologic cream: An assessment of both doxepin antipruritic action and doxepin action as an inhibitor of papules, in allergen and histamine-caused pruritus. Allergol Immunopathol (Madr). 1999;27:265–70.PubMed

140.

Eschler DC, Klein PA. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J Drugs Dermatol. 2010;9:992–7.PubMed

141.

Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream The doxepin study group. J Am Acad Dermatol. 1994;31:613–6. https://doi.org/10.1016/s0190-9622(94)70225-x.CrossRefPubMed

142.

Drake LA, Cohen L, Gillies R, et al. Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis. J Am Acad Dermatol. 1999;41:209–14. https://doi.org/10.1016/s0190-9622(99)70051-4.CrossRefPubMed

143.

Zell-Kanter M, Toerne TS, Spiegel K, Negrusz A. Doxepin toxicity in a child following topical administration. Ann Pharmacother. 2000;34:328–9. https://doi.org/10.1345/aph.19170.CrossRefPubMed

144.

Mahmoud RH, Mahmoud O, Biazus Soares G, Yosipovitch G. Novel topical treatments for itch. Dermatol Ther (Heidelb). 2024;14:829–40. https://doi.org/10.1007/s13555-024-01144-w.CrossRefPubMedPubMedCentral

145.

Silverberg JI, Lio PA, Simpson EL, et al. Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial. EClinicalMedicine. 2023;60: 102002. https://doi.org/10.1016/j.eclinm.2023.102002.CrossRefPubMedPubMedCentral

146.

Schut C, Mollanazar NK, Kupfer J, Gieler U, Yosipovitch G. Psychological interventions in the treatment of chronic itch. Acta Derm Venereol. 2016;96:157–61. https://doi.org/10.2340/00015555-2177.CrossRefPubMed

147.

van Laarhoven AIM, van der Sman-Mauriks IM, Donders ART, Pronk MC, van de Kerkhof PCM, Evers AWM. Placebo effects on itch: a meta-analysis of clinical trials of patients with dermatological conditions. J Invest Dermatol. 2015;135:1234–43. https://doi.org/10.1038/jid.2014.522.CrossRefPubMed

148.

Pousti BT, Valdes-Rodriguez R. Use of dupilumab in severe, multifactorial, chronic itch for geriatric patients. Cutis. 2022;110:e31–2. https://doi.org/10.12788/cutis.0689.CrossRefPubMed

Titel: Topical Medications for Chronic Itch in Older Patients: Navigating a Pressing Need
verfasst von: Brooke Bartley
Christina Pierce
Chad Hivnor
Rodrigo Valdes-Rodriguez
Publikationsdatum: 30.01.2025
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 3/2025
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-024-01174-1

Dementia Medications and Their Association with Pain Medication Use in Medicare Beneficiaries with Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Chronic Pain

Open Access
Original Research Article

Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults with Variable Disease States: A Meta-analysis of Large Placebo-Controlled Trials

Review Article

An Educational Intervention to Promote Central Nervous System-Active Deprescribing in Dementia: A Pilot Study

Original Research Article

Executive Summary: Treatment of Osteoporosis and Osteoarthritis in the Oldest Old

Commentary

Perioperative Anticholinergic Medication Use and Incident Dementia among Older Surgical Patients: a Retrospective Cohort Study using Real-World Data

Original Research Article

Antidepressants to Manage Osteoarthritic Pain: The Value of Pain Phenotyping

Open Access
Current Opinion

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Krebsscreeningprogramme erreichen Menschen mit kognitiver Beeinträchtigung schlechter

14.03.2025
Früherkennungsuntersuchung
Nachrichten

Daten aus den Niederlanden zeigen, dass Krebsfrüherkennungsmaßnahmen für Menschen mit Störungen der Intelligenzentwicklung häufig nicht zugänglich sind. Wie kann diese Lücke geschlossen werden?

Perkutane Ablation – ungenutztes Potenzial für die Schmerztherapie?

12.03.2025
Tumorschmerz
Nachrichten

Geht es nach US-Versicherungsdaten, ist die perkutane Ablation eine vorteilhafte, aber zu selten genutzte Option in der Schmerzlinderung von Personen mit bestimmten Tumoren. Wichtige Fragen bleiben allerdings unbeantwortet.

Reduzieren Kälte und Kompression die CIPN-Gefahr in den Händen?

12.03.2025
Nebenwirkungen der Krebstherapie
Nachrichten

Ergebnisse der deutschen POLAR-Studie sprechen dafür, dass kühlende oder komprimierende Handschuhe das Risiko für eine Taxan-induzierte periphere Neuropathie senken können. Ein paar Fragen bleiben aber offen.

Spricht eine hohe eGFR-Variabilität für eine ungünstige Prognose?

12.03.2025
Chronische Nierenerkrankung
Nachrichten

Variiert die geschätzte glomeruläre Filtrationsleistung von Messung zu Messung deutlich, ist das bei Menschen mit chronischer Niereninsuffizienz ein ungünstiges Zeichen, nicht nur mit Blick auf die Niere. Dafür spricht zumindest eine Auswertung der CRIC-Studie.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Topical Medications for Chronic Itch in Older Patients: Navigating a Pressing Need

Abstract

Weitere Artikel der Ausgabe 3/2025

Dementia Medications and Their Association with Pain Medication Use in Medicare Beneficiaries with Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Chronic Pain

Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults with Variable Disease States: A Meta-analysis of Large Placebo-Controlled Trials

An Educational Intervention to Promote Central Nervous System-Active Deprescribing in Dementia: A Pilot Study

Executive Summary: Treatment of Osteoporosis and Osteoarthritis in the Oldest Old

Perioperative Anticholinergic Medication Use and Incident Dementia among Older Surgical Patients: a Retrospective Cohort Study using Real-World Data

Antidepressants to Manage Osteoarthritic Pain: The Value of Pain Phenotyping

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Innere Medizin

Krebsscreeningprogramme erreichen Menschen mit kognitiver Beeinträchtigung schlechter

Perkutane Ablation – ungenutztes Potenzial für die Schmerztherapie?

Reduzieren Kälte und Kompression die CIPN-Gefahr in den Händen?

Spricht eine hohe eGFR-Variabilität für eine ungünstige Prognose?

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten